Monitor upcoming top-line data from the FURVENT Phase 3 trial of firmonertinib in EGFR exon20ins NSCLC, which could be a near-term catalyst. ARR-002 remains preclinical with no IND filing date disclosed.
Price Chart
Executive Summary
ArriVent BioPharma presented preclinical data at AACR 2026 for two pipeline candidates: firmonertinib, an EGFR inhibitor with activity against exon 20 insertion NSCLC, and ARR-002, a novel dual-target ADC for ovarian and endometrial cancers. The data highlight structural and mechanistic rationale for clinical development but contain no new clinical results or regulatory decisions.
Key Facts
- Presented preclinical data for firmonertinib showing broad activity against EGFR exon 20 insertion and classical mutations, supporting ongoing Phase 3 FURVENT trial.
- Firmonertinib has FDA Breakthrough Therapy and Orphan Drug designations but no new regulatory updates in this release.
- Co-presented preclinical data for ARR-002 (AV-P138-ADC), a first-in-class dual-target MUC16/NaPi2b tetravalent ADC, showing superior internalization and efficacy in ovarian cancer models.
- ARR-002 demonstrated a favorable tolerability profile in non-human primates with reversible hematologic findings at high doses.
- No clinical trial results, revenue figures, or financial metrics were disclosed.
Financial Impact
No immediate financial impact; data support future clinical potential but no commercial or earnings implications in near term.
Risk Factors
- Preclinical data may not translate to clinical efficacy in humans.
- No timeline provided for initiation of clinical trials for ARR-002, creating uncertainty around development pace.
- Firmonertinib is already approved in China but faces competitive landscape in U.S. for EGFR-mutant NSCLC.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257720 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $23.64 | awaiting T+5 | — | $14.86 (−37.14%) |
Oct 25, 2026 1d ago | Press Release | $21.00 | awaiting T+5 | — | $14.86 (−29.24%) |
Oct 23, 2026 2d ago | Press Release | $21.00 | awaiting T+5 | — | $14.86 (−29.24%) |
Oct 19, 2026 7d ago | 8-K | $17.94 | awaiting T+5 | — | $14.86 (−17.17%) |
Oct 13, 2026 12d ago | SC 13G | $16.20 $19.12 | ▲ +18.02% | ▲ +17.57% | $14.86 (−8.27%) |
Oct 13, 2026 13d ago | 8-K | $16.09 $18.85 | ▲ +17.15% | ▲ +18.31% | $14.86 (−7.64%) |
Oct 8, 2026 17d ago | SC 13D/A | $16.73 $16.66 | ▲ +0.42% | ▼ −1.55% | $14.86 (+11.18%) |
Oct 6, 2026 20d ago | 8-K | $15.09 $16.09 | ▼ −6.63% | ▼ −6.77% | $14.86 (+1.52%) |
Aug 12, 2026 10w ago | Press Release | $30.00 $29.18 | ▲ +2.73% | ▲ +0.77% | $14.86 (+50.47%) |
Jun 11, 2026 19w ago | Institutional Cluster | $30.54 $31.74 | ▲ +3.93% | ▲ +3.26% | $14.86 (−51.34%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers